Technologies

This is a high-throughput sequencing based method to map euchromatin and heterochromatin accessibility. The method is based on the sequential extraction of distinct nuclear fractions containing: soluble proteins (S1 fraction); the surnatant obtained after DNase treatment (S2 fraction); DNase-resistant chromatin extracted with high salt buffer (S3 fraction); and the most condensed and insoluble portion of chromatin, extracted with urea buffer that solubilizes the remaining proteins and membranes (S4 fraction).

The proposing team that works at CNR ISTEC has recently patented a technology for the production of the Smart Polycrystals (SP), i.e. transparent YAG-based ceramic polycrystals (Y₃Al₅O₁₂) variably doped with rare earths ions and transition metals ions. The SPs solve the problem of the reduction of the efficiency in the solid state laser systems caused by the inhomogeneous heating of the single crystals during the emission process.

The technology refers to a system for the safety and control of the mobility of vehicles, pedestrians, and mass transport users, in conventional and advanced contexts and is suitable for use as an infrastructure for the production/sharing of information and data, aimed at monitoring and intervention in critical areas by offering specific functions concerning the detection of potentially dangerous situations or the optimization of resources.

This form describes a programmable, autonomous and stand-alone imaging system for the acquisition and processing of images containing subjects whose size is larger than 1cm (e.g. gelatinous zooplankton, fishes, litter, manufacts), form the seafloor or along the water column, in shallow or deep waters. It is capable to recognize and classify the image content through pattern recognition algorithms that combine computer vision and artificial intelligence methodologies.

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.

Our treatment demonstrated the ability to kill metastatic human melanoma cells, for which there are very few effective therapeutic approaches. Use of a specific Essential Oil (EO) to inhibit the replication of human metastatic melanoma cells. This EO can be used both for direct application to the skin, and administered by mouth to reach both primary and metastatic melanomas.